189 related articles for article (PubMed ID: 29382784)
1. KIF22 coordinates CAR and EGFR dynamics to promote cancer cell proliferation.
Pike R; Ortiz-Zapater E; Lumicisi B; Santis G; Parsons M
Sci Signal; 2018 Jan; 11(515):. PubMed ID: 29382784
[TBL] [Abstract][Full Text] [Related]
2. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway.
Ravi J; Sneh A; Shilo K; Nasser MW; Ganju RK
Oncotarget; 2014 May; 5(9):2475-86. PubMed ID: 24811863
[TBL] [Abstract][Full Text] [Related]
3. Generation and evaluation of a chimeric antibody against coxsackievirus and adenovirus receptor for cancer therapy.
Sakamoto S; Inoue H; Kaneko MK; Ogasawara S; Kajikawa M; Urano S; Ohba SI; Kato Y; Kawada M
Cancer Sci; 2019 Nov; 110(11):3595-3602. PubMed ID: 31512325
[TBL] [Abstract][Full Text] [Related]
4. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
Wu W; O'Reilly MS; Langley RR; Tsan RZ; Baker CH; Bekele N; Tang XM; Onn A; Fidler IJ; Herbst RS
Mol Cancer Ther; 2007 Oct; 6(10):2652-63. PubMed ID: 17913856
[TBL] [Abstract][Full Text] [Related]
5. KIF22 promotes the proliferation and glycolysis of melanoma by activating EGFR/STAT3 signaling.
Zhong Z; Zhong H
Clinics (Sao Paulo); 2023; 78():100307. PubMed ID: 37944197
[TBL] [Abstract][Full Text] [Related]
6. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Galvani E; Giovannetti E; Saccani F; Cavazzoni A; Leon LG; Dekker H; Alfieri R; Carmi C; Mor M; Ardizzoni A; Petronini PG; Peters GJ
Neoplasia; 2013 Jan; 15(1):61-72. PubMed ID: 23359111
[TBL] [Abstract][Full Text] [Related]
8. KIF22 promotes bladder cancer progression by activating the expression of CDCA3.
Li K; Li S; Tang S; Zhang M; Ma Z; Wang Q; Chen F
Int J Mol Med; 2021 Dec; 48(6):. PubMed ID: 34633053
[TBL] [Abstract][Full Text] [Related]
9. Suppression of KIF22 Inhibits Cell Proliferation and Xenograft Tumor Growth in Tongue Squamous Cell Carcinoma.
Liu Y; Li RH; Ren G; Jiang J
Biomed Res Int; 2020; 2020():6387545. PubMed ID: 32090103
[TBL] [Abstract][Full Text] [Related]
10. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
11. mPRα mediates P4/Org OD02-0 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway.
Lu X; Guan A; Chen X; Xiao J; Xie M; Yang B; He S; You S; Li W; Chen Q
Mol Carcinog; 2020 Feb; 59(2):179-192. PubMed ID: 31777985
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer effects of REIC/Dkk-3-encoding adenoviral vector for the treatment of non-small cell lung cancer.
Shien K; Tanaka N; Watanabe M; Soh J; Sakaguchi M; Matsuo K; Yamamoto H; Furukawa M; Asano H; Tsukuda K; Nasu Y; Huh NH; Miyoshi S; Kumon H; Toyooka S
PLoS One; 2014; 9(2):e87900. PubMed ID: 24498395
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung Adenocarcinoma.
Zhou X; Guo J; Ji Y; Pan G; Liu T; Zhu H; Zhao J
Mol Cancer Res; 2016 May; 14(5):448-57. PubMed ID: 26896556
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine-1-phosphate receptor-3 signaling up-regulates epidermal growth factor receptor and enhances epidermal growth factor receptor-mediated carcinogenic activities in cultured lung adenocarcinoma cells.
Hsu A; Zhang W; Lee JF; An J; Ekambaram P; Liu J; Honn KV; Klinge CM; Lee MJ
Int J Oncol; 2012 May; 40(5):1619-26. PubMed ID: 22344462
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells.
Su Z; Yin J; Zhao L; Li R; Liang H; Zhang J; Wang K
World J Surg Oncol; 2014 Dec; 12():367. PubMed ID: 25441176
[TBL] [Abstract][Full Text] [Related]
16. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
[TBL] [Abstract][Full Text] [Related]
17. Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells.
Iguchi K; Sakurai F; Tomita K; Katayama K; Yamaguchi T; Kawabata K; Tagawa M; Kawabata M; Shirakawa T; Mizuguchi H
Cancer Gene Ther; 2012 Feb; 19(2):118-25. PubMed ID: 22076042
[TBL] [Abstract][Full Text] [Related]
18. Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR.
Jung SK; Lee MH; Lim DY; Kim JE; Singh P; Lee SY; Jeong CH; Lim TG; Chen H; Chi YI; Kundu JK; Lee NH; Lee CC; Cho YY; Bode AM; Lee KW; Dong Z
J Biol Chem; 2014 Dec; 289(52):35839-48. PubMed ID: 25368326
[TBL] [Abstract][Full Text] [Related]
19. KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway.
Zhai M; Miao J; Zhang R; Liu R; Li F; Shen Y; Wang T; Xu X; Gao G; Hu J; He A; Bai J
J Cancer Res Clin Oncol; 2024 May; 150(5):239. PubMed ID: 38713252
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
